Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 2/20 | 0.53 |
| ▸ | HTR1B | P28222 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2379228 | 0.88 | HPGD (0.77) | HPGDMEN1KMT2APOLBTSHR | |
| SCHEMBL9300442 | 0.87 | HPGD (0.71) | HPGDMEN1KMT2APOLBTSHR | |
| SCHEMBL848798 | 0.87 | HPGD (0.77) | HPGDMEN1KMT2APOLBTSHR | |
| SCHEMBL2378485 | 0.86 | HPGD (0.77) | HPGDMEN1KMT2APOLBTSHR | |
| SCHEMBL2376496 | 0.86 | HPGD (0.77) | HPGDMEN1KMT2APOLBTSHR | |
| SCHEMBL13503858 | 0.85 | HPGD (0.67) | HPGDMEN1KMT2APOLBTSHR | |
| SCHEMBL848003 | 0.85 | HPGD (0.56) | HPGDMEN1KMT2APOLBTSHR | |
| SCHEMBL2377982 | 0.84 | KMT2A (0.59) | HPGDMEN1KMT2APOLBTSHR | |
| SCHEMBL2378904 | 0.84 | ALDH1A1 (0.56) | HPGDKMT2APOLBTSHRALDH1A1 | |
| SCHEMBL24556567 | 0.84 | AKR1C1 (0.59) | HPGDKMT2ATSHRALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| EP-1373224-B1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER LAMBERT CO (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1801106-A2 | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-7214676-B2 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-20040214843-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | PFIZER INC | 2004-10-28 | — | — | US | disclosed |
| CN-1498212-A | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | ��������ʲ��������ι�˾ | 2004-05-19 | — | — | CN | disclosed |
| EP-1373224-A1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | Warner-Lambert Company LLC (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020198198-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY LLC | 2002-12-26 | — | — | US | disclosed |
| WO-2002074754-A1 | NEW SPIROTRICYCLIC DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-1098892-A1 | BIPHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000005225-A1 | BIPHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198198-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | PDE3A, PDE12, PDE5A | HPGD 263/4885MEN1 1497/4885KMT2A 2878/4885 |
| US-20040214843-A1 | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | PDE3A, PDE12, PDE5A | HPGD 263/4885MEN1 1497/4885KMT2A 2878/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | HPGD 2068/4885MEN1 276/4885KMT2A 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.